Hey Rob,I'm curious what you think of the ISRG move. I know that they're always fending off studies and commentary, but this seems a little larger than normal. Multiple credible sources are questioning the economics and the FDA incident review is piling on at the same time.The thing I like the least is last evening's reversal on the increase in incident frequency. When the FDA initiated the review, ISRG's initial comment was a denial that there was an increase in reportable incidents. Then they come out yesterday ans say there was an increase, but it was due to how they've reclassified certain incidents.Intuitive Surgical Inc. (ISRG) said changes in how it reports adverse events resulted in an increased number of reports sent to U.S. regulators, as well as more incidents being classified as resulting in serious injury. The company, maker of the da Vinci robotic surgery machines, said the rise in adverse event reporting "does not reflect a change in product performance."-Dow JOnes NewswireIt's don't care for that news. The price action has also swung radically. I decided to protect my gains and closed the position at a nice gain. Not as nice as it could have been, and I still like the company a lot. I just don't like the idea of fighting the tape in a market that feels a little top heavy. Thoughts?Peter(Sorry for the OT guys...)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Esti